MPO and systemic inflammatory response syndrome: The results suggested that MPO levels were significantly lowered in the h‐mIL‐6R mAb‐ and Tocilizumab‐treated SIRS mice (Figure 3D), suggesting that inflammation in lung tissue was lessened by the IL‐6R mAbs.